Literature DB >> 33712562

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Paul G Richardson1, Thierry Facon2, William I Bensinger3, Xavier Leleu4, Frank Campana5,6, Sandrine Macé7, Marielle Chiron7, Helgi van de Velde5, Joseph Mikhael8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33712562      PMCID： PMC7954817          DOI： 10.1038/s41408-021-00438-y

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  11 in total

1.  In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab.

Authors:  Djordje Atanackovic; Sara Yousef; Christa Shorter; Srinivas K Tantravahi; Mary Steinbach; Fiorella Iglesias; Douglas Sborov; Sabarinath Venniyil Radhakrishnan; Marielle Chiron; Rodney Miles; Mohamed Salama; Nicolaus Kröger; Tim Luetkens
Journal:  Leukemia       Date:  2019-08-13       Impact factor: 11.528

2.  Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.

Authors:  Xiaoyan Feng; Li Zhang; Chirag Acharya; Gang An; Kenneth Wen; Lugui Qiu; Nikhil C Munshi; Yu-Tzu Tai; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2017-03-01       Impact factor: 12.531

3.  CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.

Authors:  Inger S Nijhof; Tineke Casneuf; Jeroen van Velzen; Berris van Kessel; Amy E Axel; Khaja Syed; Richard W J Groen; Mark van Duin; Pieter Sonneveld; Monique C Minnema; Sonja Zweegman; Christopher Chiu; Andries C Bloem; Tuna Mutis; Henk M Lokhorst; A Kate Sasser; Niels W C J van de Donk
Journal:  Blood       Date:  2016-06-15       Impact factor: 22.113

4.  SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.

Authors:  Jutta Deckert; Marie-Cécile Wetzel; Laura M Bartle; Anna Skaletskaya; Victor S Goldmacher; François Vallée; Qing Zhou-Liu; Paul Ferrari; Stéphanie Pouzieux; Charlotte Lahoute; Charles Dumontet; Adriana Plesa; Marielle Chiron; Pascale Lejeune; Thomas Chittenden; Peter U Park; Véronique Blanc
Journal:  Clin Cancer Res       Date:  2014-07-01       Impact factor: 12.531

5.  A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Authors:  Joseph Mikhael; Paul Richardson; Saad Z Usmani; Noopur Raje; William Bensinger; Chatchada Karanes; Frank Campana; Dheepak Kanagavel; Franck Dubin; Qianying Liu; Dorothée Semiond; Kenneth Anderson
Journal:  Blood       Date:  2019-03-12       Impact factor: 22.113

Review 6.  CD38 antibodies in multiple myeloma: back to the future.

Authors:  Niels W C J van de Donk; Paul G Richardson; Fabio Malavasi
Journal:  Blood       Date:  2017-11-08       Impact factor: 22.113

Review 7.  Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2016-07       Impact factor: 10.047

8.  Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.

Authors:  Paul G Richardson; Michel Attal; Frank Campana; Solenn Le-Guennec; Ai-Min Hui; Marie-Laure Risse; Kathryn Corzo; Kenneth C Anderson
Journal:  Future Oncol       Date:  2017-12-22       Impact factor: 3.404

Review 9.  Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.

Authors:  Thomas G Martin; Kathryn Corzo; Marielle Chiron; Helgi van de Velde; Giovanni Abbadessa; Frank Campana; Malini Solanki; Robin Meng; Helen Lee; Dmitri Wiederschain; Chen Zhu; Alexey Rak; Kenneth C Anderson
Journal:  Cells       Date:  2019-11-26       Impact factor: 6.600

10.  A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism.

Authors:  Niken M Mahaweni; Timo I Olieslagers; Ivan Olivares Rivas; Stefan J J Molenbroeck; Mathijs Groeneweg; Gerard M J Bos; Marcel G J Tilanus; Christina E M Voorter; Lotte Wieten
Journal:  Sci Rep       Date:  2018-10-29       Impact factor: 4.379
View more
  1 in total

1.  Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma.

Authors:  Haibo Sun; Thomas G Martin; John Marra; Denice Kong; Jonathon Keats; Sandrine Macé; Marielle Chiron; Jeffrey L Wolf; Jeffrey M Venstrom; Raja Rajalingam
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.